Article Text
PDF
Abstract
Background Before implementing screening programmes for acute HIV infection in developing countries, key issues, including cost, feasibility and public health impact, must be determined.
Objective Fourth-generation enzyme immunoassay (EIA) was compared with HIV-1 RNA PCR for the detection of acute and early HIV infection in counselling and testing populations in Lima, Peru.
Methods Adults presenting for HIV testing at designated clinics in Lima-Callao, Peru were offered additional screening for acute HIV infection. All serum samples were tested with fourth-generation Ag/Ab EIA and confirmed by line immunoassay. Negative specimens were combined into 50-sample pools for HIV-1 RNA screening by PCR analysis in standard pooling algorithms. RNA-positive samples were retested with a third-generation EIA to evaluate the relative sensitivity of standard testing procedures.
Results Between 2007 and 2008 1191 participants were recruited. The prevalence of HIV infection was 3.2% (38/1191; 95% CI 2.2% to 4.2%) overall and 10.5% (25/237; 95% CI 6.6% to 14.5%) among men who reported sex with men (MSM). The prevalence of acute or recent HIV infection was 0.2% (95% CI 0% to 0.4%) overall and 0.8% (95% CI 0% to 2.0%) among MSM. Compared with third-generation EIA testing, both fourth-generation EIA and RNA PCR increased the rate of HIV case identification by 5.3% overall and by 8.0% within the subpopulation of MSM.
Conclusions Screening for acute HIV infection within Peru's resource-limited public health system was acceptable and detected a high prevalence of acute and recent HIV infection among MSM. Additional efforts are needed to screen for, and prevent, transmission of HIV among MSM in Peru during the acute seroconversion stage.
- Acute HIV infection
- pooled RNA testing
- Peru: men who have sex with men
- HIV testing
- homosexuality
- PCR
- STD surveillance
Statistics from Altmetric.com
- Acute HIV infection
- pooled RNA testing
- Peru: men who have sex with men
- HIV testing
- homosexuality
- PCR
- STD surveillance
Introduction
Screening for acute and recent HIV infection provides new opportunities for HIV treatment and prevention. Nucleic acid analysis is the ‘gold standard’ for diagnosing acute and recent HIV infection, though the technical requirements often exceed developing country resources.1–5 Fourth-generation enzyme immunoassay (EIA; which adds a p24 antigen component to the third-generation antibody assay) is also effective in detecting acute and recent HIV infection and adaptable to the existing infrastructure of many developing areas.6 We report the results of a pilot programme to screen for acute and recent HIV infection in Lima, Peru, comparing pooled HIV-1 RNA nucleic acid analysis and fourth-generation EIA with the standard of care third-generation EIA/line immunoassay (LIA) testing algorithm.
Methods
Adults seeking HIV testing at the Barton Health Centre in Lima, Peru between December 2007 and May 2008 were offered supplementary screening for acute and recent HIV infection. The protocol was approved by the institutional review boards of the University of California, Los Angeles, Universidad Peruana Cayetano Heredia and US Naval Medical Research Center.
Specimens were screened with a fourth-generation EIA to detect HIV-1/2 IgG and IgM antibodies and/or HIV-1 p24 antigen (Vironostika Uni-Form II; Biomerieux, Marcy-L'Etoile, France). Positive samples were confirmed by HIV-1/2 LIA (Inno-Lia HIV I/II Score; Innogenetics, Ghent, Belgium). Samples negative or indeterminate by fourth-generation EIA or LIA were aggregated into pools of 50 and screened for HIV-1 RNA (Roche Taqman, Basel, Switzerland) using a 50:10:1 algorithm.2 7 RNA-positive samples were subsequently tested with a third-generation EIA capable of detecting HIV-1/2 IgG and IgM but not p24 antigen (Genetic Systems HIV-1/-2 Plus O; Bio-Rad, Hercules, California, USA).
Samples positive by fourth-generation EIA and/or RNA PCR, but negative by third-generation EIA (p24 Ag+; IgG/IgM-), were defined as acute infection. Samples positive by third- and fourth-generation EIA (p24 Ag+; IgG/IgM+), but negative or indeterminate by LIA were classified as recent infection. Only samples positive by LIA, meeting Peruvian Ministry of Health criteria for the diagnosis of HIV infection, were diagnosed as chronic infection.
Results
One thousand, three hundred and ninety-one men and women requested HIV testing during the study period. One thousand, one hundred and ninety-one (85.6%) consented to additional blood being taken to screen for acute or recent HIV infection (figure 1).
Diagnostic algorithm and results of screening for acute and recent HIV infection; Lima, Peru 2007–8. EIA, enzyme immunoassay; LIA, line immunoassay.
The prevalence of HIV infection in the study population was 3.2% (38/1191; 95% CI 2.2% to 4.2%) and the prevalence of acute or recent infection was 0.2% (2/1191; 95% CI 0% to 0.4%). The prevalence of HIV among men who have sex with men (MSM) was 10.5% (25/237; 95% CI 6.6% to 14.5%), including both cases of acute or recent infection (2/237; 0.8%, 95% CI 0% to 2.0%). Compared with the standard of care EIA/LIA algorithm, fourth-generation EIA with RNA PCR confirmation increased the frequency of HIV diagnosis by 5.3% (CI 0% to 12.3%) overall and by 8.0% (CI 0% to 18.6%) among MSM.
Discussion
In our evaluation of 1191 men and women, we identified two cases of acute or recent HIV infection that would not have been diagnosed using Peru's standard of care screening and confirmation algorithm. While HIV-1 RNA and fourth-generation EIA assays were both effective in screening for acute or recent infection, there were significant differences of cost and complexity associated with the different assays. Implementation of RNA-based testing requires substantial investment in training and infrastructure while the technical demands of fourth-generation EIA are similar to currently used assays. In contrast, while RNA PCR can screen for, and confirm, HIV infection, fourth-generation EIA is not as specific and often requires an additional confirmatory assay for definitive diagnosis. The introduction of rapid fourth-generation assays that differentiate the presence of HIV p24 antigen from IgG/IgM antibody may contribute to use of fourth-generation EIA as a single screening and confirmation assay.
The small number of participants in our pilot study limits any conclusions about the sensitivity or specificity of the different assays. Our inclusion of specimens positive by fourth-generation EIA but negative or indeterminate by LIA in the pooled nucleic acid analysis algorithm may have increased costs compared with individual RNA testing of these specimens. Finally, recent modification of Peruvian HIV testing protocols to include rapid antibody testing could alter the context and utility of screening for acute and recent HIV infection in the country.
Our findings establish the acceptability and performance of fourth-generation EIA and pooled HIV-1 RNA PCR assays for the diagnosis of acute and recent HIV infections within a resource-limited public health system and identify a high prevalence of acute and recent HIV seroconversion among MSM in Peru. Future public health efforts should address cost-effective methods to increase detection of acute and recent infection among MSM in Latin America.
Key messages
Both HIV-1 RNA PCR and p24 antigen assays are effective and acceptable methods of screening for acute and recent HIV infection in developing countries.
Significant differences in cost and infrastructural requirements exist between the different assays.
Among men who have sex with men (MSM) in urban Peru, the prevalence of HIV infection at any stage was 10.5% and the prevalence of acute or recent infection was 0.8%.
Screening for acute and recent HIV infection in Lima, Peru increased HIV case detection rate by 5.3% overall and by 8.0% among MSM.
Acknowledgments
We are grateful to Dr Doris Chunga and the counselling and laboratory staff of the Centro de Salud/Centro de Referencia de ITS Alberto Barton; Antonio Flores, Jorge Maguina, Carlos Villa and the staff of the Universidad Peruana Cayetano Heredia Unidad de Salud Sexual y Derechos Humanos; and Gloria Chauca, Merly Sovero and the staff of the Virology Laboratory of the US Naval Medical Center Research Laboratory Detachment, Lima, Peru.
Footnotes
Parts of the data reported were previously presented at the International Society for STD Research Meeting (London, UK; June, 2009).
Funding JLC was previously supported by NIH T32 MH080634 and is currently supported by NIH K23 MH084611. Additional support was provided by the UCLA AIDS Institute/Center for AIDS Research. Disclaimer: The views expressed in this article are those of the author and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, nor the US Government. LCDR TK is a military service member and SM is an employee of the US Government. This work was prepared as part of their official duties. Title 17 U.S.C. § 105 provides that ‘Copyright protection under this title is not available for any work of the United States government’. Title 17 U.S.C. § 101 defines a US Government work as a work prepared by a military service member or employee of the US Government as part of that person's official duties.
Competing interests None.
Ethics approval This study was conducted with the approval of the University of California, Los Angeles Universidad Peruana Cayetano Heredia US Naval Medical Research Center.
Provenance and peer review Not commissioned; externally peer reviewed.